Review article · 2020 · Open access

Nanomedicine in Pancreatic Cancer: A New Hope for Treatment

Pablo Redruello Guerrero, Gloria Perazzoli, Ana Luisa Cepero, Francisco Quiñonero, Cristina Mesas, Kevin Doello, Antonio Jesús Láinez Ramos‐Bossini, Mario Rivera‐Izquierdo, Consolación Melguizo, Jose Carlos Prados

Current Drug Targets, 21(15), 1580–1592 · Published 3 July 2020 · DOI 10.2174/1389450121666200703195229

Open PDFView at the publisherCite this paper

In brief

“Nanomedicine in Pancreatic Cancer: A New Hope for Treatment” is a 2020 review article by Pablo Redruello Guerrero and 9 co-authors, published in Current Drug Targets. OpenAlex counts 7 citations as of 21 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Institutional Repository of the University of Granada (University of Granada).

Citations
7
Most cited in
2022 (2)
Field-weighted impact
0.06
References
123
Authors
10

Abstract

Pancreatic ductal adenocarcinoma (PDA) has one of the worst prognosis and higher mortality among most cancers. The diagnosis of PDA is frequently delayed due to a lack of specific biomarkers, and the efficacy of current chemotherapeutic drugs is limited. Moreover, chemotherapy is generally applied in advanced stages, where metastatic spread has already occurred. Nanotechnologybased systems are allowing to advance in the diagnosis and treatment of PDA. New nanoformulations have shown to improve the activity of conventional chemotherapeutic agents, such as gemcitabine, and new antitumor drugs, protecting them from degradation, improving their selectivity, solubility and bioavailability, and reducing their side effects. Moreover, the design of nanocarriers represents a new way to overcome drug resistance, which requires a comprehensive understanding of the tumor microenvironment of PDA. This article reviews the current perspectives, based on nanomedicine, to address the limitations of pancreatic cancer treatment, and the futures lines of research to progress in the control of this disease.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Guerrero, P. R., Perazzoli, G., Cepero, A. L., Quiñonero, F., Mesas, C., Doello, K., Ramos‐Bossini, A. J. L., Rivera‐Izquierdo, M., Melguizo, C., & Prados, J. C. (2020). Nanomedicine in Pancreatic Cancer: A New Hope for Treatment. Current Drug Targets, 21(15), 1580–1592. https://doi.org/10.2174/1389450121666200703195229

MLA 9

Guerrero, Pablo Redruello, et al. “Nanomedicine in Pancreatic Cancer: A New Hope for Treatment.” Current Drug Targets, vol. 21, no. 15, 2020, pp. 1580–1592. https://doi.org/10.2174/1389450121666200703195229.

Chicago

Guerrero, Pablo Redruello, Gloria Perazzoli, Ana Luisa Cepero, Francisco Quiñonero, Cristina Mesas, Kevin Doello, Antonio Jesús Láinez Ramos‐Bossini, Mario Rivera‐Izquierdo, Consolación Melguizo, and Jose Carlos Prados. 2020. “Nanomedicine in Pancreatic Cancer: A New Hope for Treatment.” Current Drug Targets 21 (15): 1580–1592. https://doi.org/10.2174/1389450121666200703195229.

Harvard

Guerrero, P. R. et al. (2020) ‘Nanomedicine in Pancreatic Cancer: A New Hope for Treatment’, Current Drug Targets, 21(15), pp. 1580–1592. doi:10.2174/1389450121666200703195229.

IEEE

P. R. Guerrero et al., “Nanomedicine in Pancreatic Cancer: A New Hope for Treatment,” Current Drug Targets, vol. 21, no. 15, pp. 1580–1592, 2020, doi: 10.2174/1389450121666200703195229.

BibTeX

@article{guerrero2020nanomedicine,
  title     = {{Nanomedicine in Pancreatic Cancer: A New Hope for Treatment}},
  author    = {Guerrero, Pablo Redruello and Perazzoli, Gloria and Cepero, Ana Luisa and Quiñonero, Francisco and Mesas, Cristina and Doello, Kevin and Ramos‐Bossini, Antonio Jesús Láinez and Rivera‐Izquierdo, Mario and Melguizo, Consolación and Prados, Jose Carlos},
  journal   = {Current Drug Targets},
  year      = {2020},
  volume    = {21},
  number    = {15},
  pages     = {1580--1592},
  doi       = {10.2174/1389450121666200703195229},
  url       = {https://doi.org/10.2174/1389450121666200703195229}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202222
202322
202411
202522

Its field-weighted citation impact is 0.06: it has been cited 0.06 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery

  • pancreatic ductal adenocarcinoma
  • nanomedicine
  • nanocarriers
  • gemcitabine
  • drug delivery
  • drug resistance
  • tumor microenvironment
  • chemotherapy

Work with this paper

Most-cited papers in Materials Science

All highly cited Materials Science papers

Questions about this paper

How do I cite this paper in APA style?

Guerrero, P. R., Perazzoli, G., Cepero, A. L., Quiñonero, F., Mesas, C., Doello, K., Ramos‐Bossini, A. J. L., Rivera‐Izquierdo, M., Melguizo, C., & Prados, J. C. (2020). Nanomedicine in Pancreatic Cancer: A New Hope for Treatment. Current Drug Targets, 21(15), 1580–1592. https://doi.org/10.2174/1389450121666200703195229

How many times has this paper been cited?

7 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Institutional Repository of the University of Granada (University of Granada): sign in and open the PDF from this page.

Who wrote this paper?

Pablo Redruello Guerrero, Gloria Perazzoli, Ana Luisa Cepero, Francisco Quiñonero, Cristina Mesas, Kevin Doello, Antonio Jesús Láinez Ramos‐Bossini, Mario Rivera‐Izquierdo, Consolación Melguizo, Jose Carlos Prados.

What is the DOI of this paper?

10.2174/1389450121666200703195229, permanently at https://doi.org/10.2174/1389450121666200703195229. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.